NRx Pharmaceuticals, an international company traded on Nasdaq, will complete the clinical trials needed to increase the statistical sample and to prepare the necessary regulatory files in order to continue the clinical trials and conduct its third phase. The company will conduct clinical trials on tens of thousands of volunteers in the countries with which it has signed cooperation agreements. IIBR will accompany the process and will continue to share knowledge and provide scientific assistance to complete the clinical trials.
Prof. Shmuel Shapira: “I understand, I sympathize and I'm doing my best to rectify the situation. It’s unfair to discriminate this honorable population. They deserve to receive this certificate.”
Information regarding our vaccine’s clinical trials and list of medical centers taking part in the research
Defense Minister, Benny Gantz: "The scientists of the IIBR are Israel's 'elite unit, and have taken on an extremely important task - saving human lives. I see great importance in the development of an Israeli vaccine that will continue to serve Israeli society for years to come."
This is our vaccine's story from research to production
IIBR research and development concerning environmental sciences ranges from numerical modeling to laboratory and field experiments in the areas of meteorology and atmospheric contaminants. IIBR has developed capabilities that enable detection and identification of hazardous materials, weather and dispersion prediction, physical protection and evaluation of potential risks.
IIBR's latest Scientific Publications in the fields of biology, chemistry and the environmental sciences.
Read about IIBR in the press.